أعرض في EDS

Patient-reported outcomes during and after definitive chemoradiotherapy for oesophageal cancer

التفاصيل البيبلوغرافية
العنوان: Patient-reported outcomes during and after definitive chemoradiotherapy for oesophageal cancer
المؤلفون: Gareth Griffiths, Simon Gollins, Lisette Sheena Nixon, John Staffurth, R Roy, Stephen Falk, J I Geh, Jonathan Rees, Jane M Blazeby, Ruby Ray, N Bashir, Chris Nicholas Hurt, S. Mukherjee, Tom Crosby, David Cunningham, Tim Maughan, John Bridgewater
المصدر: Rees, J R E, Hurt, C N, Gollins, S, Mukherjee, S, Maughan, T, Falk, S J, Staffurth, J, Ray, R, Bashir, N, Geh, J I, Cunningham, D, Roy, R, Bridgewater, J, Griffiths, G, Nixon, L S, Blazeby, J M & Crosby, T 2015, ' Patient-reported outcomes during and after definitive chemoradiotherapy for oesophageal cancer ', British Journal of Cancer, vol. 113, no. 4, pp. 603-610 . https://doi.org/10.1038/bjc.2015.258
British Journal of Cancer
بيانات النشر: Springer Science and Business Media LLC, 2015.
سنة النشر: 2015
مصطلحات موضوعية: Cancer Research, medicine.medical_specialty, Esophageal Neoplasms, Cetuximab, Disease, patient reported outcomes, Antibodies, Monoclonal, Humanized, chemoradiotherapy, law.invention, Quality of life, Randomized controlled trial, law, Surveys and Questionnaires, Internal medicine, cetuximab, Insomnia, medicine, Humans, cancer, business.industry, Cancer, Chemoradiotherapy, oesophgeal, medicine.disease, Dysphagia, humanities, 3. Good health, Patient Outcome Assessment, Clinical trial, Oncology, Centre for Surgical Research, Clinical Study, Quality of Life, Physical therapy, medicine.symptom, business
الوصف: BACKGROUND:Limited data describe patient-reported outcomes (PROs) of localised oesophageal cancer treated with definitive chemoradiotherapy(CRT). The phase 2/3 SCOPE-1 trial assessed the effectiveness of CRT±cetuximab. The trial for the first time provided an opportunity to describe PROs from a multi-centre group of patients treated with CRT that are presented here.METHODS:Patients undergoing CRT±cetuximab within the SCOPE-1 trial (258 patients from 36 UK centres) completed generic-, disease- and treatment-specific health-related quality of life (HRQL) questionnaires (EORTC QLQ-C30, QLQ-OES18, Dermatology Life-Quality Index (DLQI)) at baseline and at 7, 13, 24, 52 and 104 weeks. Mean EORTC functional scale scores (>15 point change significant), DLQI scores (>4 point change significant) and proportions of patients (>15% significant) with 'minimal' or 'severe' symptoms are presented.RESULTS:Questionnaire response rates were good. At baseline, EORTC functional scores were high (>75%) and few symptoms were reported except for severe problems with fatigue, insomnia and eating-related symptoms (e.g., appetite loss, dysphagia, dry mouth) in both groups(>15%). Functional aspects of health deteriorated and symptoms increased with treatment and by week 13 global quality of life, physical, role and social function significantly deteriorated and more problems with fatigue, dyspnoea, appetite loss and trouble with taste were reported. Recovery occurred by 6 months (except severe fatigue and insomnia in >15% of patients) and maintained at follow-up with no differences between groups.CONCLUSIONS:CRT for localised oesophageal cancer has a significant detrimental impact on many aspects of HRQL; however, recovery is achieved by 6 months and maintained with the exception of persisting problems with severe fatigue and insomnia. The data suggest that the HRQL recovery after definitive CRT is quicker, and there is little lasting deficit compared with treatment including surgery. These data need to be compared with HRQL data from studies evaluating treatments including surgery for oesophageal cancer.
وصف الملف: application/pdf
تدمد: 1532-1827
0007-0920
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58bbb0db8eb042f3a9bf948a9bd0c44f
https://doi.org/10.1038/bjc.2015.258
حقوق: OPEN
رقم الأكسشن: edsair.doi.dedup.....58bbb0db8eb042f3a9bf948a9bd0c44f
قاعدة البيانات: OpenAIRE
الوصف
تدمد:15321827
00070920